Education and Counseling Checklist for Pharmacies

POMALYST Risk Evaluation and Mitigation Strategy (REMS)™ program education and prescribing safety

Authorization No.:   Confirmation No.:   Confirmation Date:

Pharmacy Name:   Pharmacy Address:

Counselor Name:   Work Phone:   Ext.:

Patient Name:   Date of Birth:

Risk Category:

Checklist for female patients of reproductive potential

☐ I will make sure that patients are aware that they will receive the Medication Guide along with their prescription

I COUNSELED ADULTS AND CHILDREN ON:

☐ Potential embryo-fetal toxicity

☐ Not taking POMALYST® (pomalidomide) if pregnant or breastfeeding

Reference ID: 3838553
☐ Using **at the same time** at least 1 highly effective method—tubal ligation, IUD, hormonal (birth controls pills, hormonal patches, injections, vaginal rings, or implants), or partner's vasectomy—and at least 1 additional effective method of birth control—male latex or synthetic condom, diaphragm, or cervical cap—**every time they have sex with a male**, or abstaining from sex with a male

☐ Continuing to use at the **same time** at least 1 highly effective method and at least 1 additional effective method of birth control beginning at least 4 weeks before taking POMALYST, while taking POMALYST, during dose interruptions, and for at least 4 weeks after stopping POMALYST **every time they have sex with a male**, or abstaining from sex with a male

☐ Obtaining a pregnancy test—performed by their healthcare provider—weekly during the first 4 weeks of use. Thereafter, pregnancy testing should be repeated every 4 weeks during the rest of their treatment in females with regular menstrual cycles or no cycle at all. If menstrual cycles are irregular, the pregnancy testing should occur every 2 weeks
The need to stop taking POMALYST right away in the event of becoming pregnant, or if they think for any reason they may be pregnant, and to call their healthcare provider immediately

Possible side effects include deep vein thrombosis, pulmonary embolism, myocardial infarction and stroke

Not sharing POMALYST capsules with anyone—especially with females who can get pregnant

Not donating blood while taking POMALYST (including dose interruptions) and for 4 weeks after stopping POMALYST

Not breaking, chewing, or opening POMALYST capsules

Instructions on POMALYST dose and administration

Milligram (mg) Strength_____ Number of Capsules Dispensed________

FEMALE CHILDREN (<18 YEARS OF AGE):

Parent or legal guardian must have read the POMALYST REMS™ education material and agreed to ensure compliance

Checklist for female patients not of reproductive potential (natural menopause for at least 24 consecutive months, a hysterectomy, and/or bilateral oophorectomy)

I will make sure that patients are aware that they will receive the Medication Guide along with their prescription

I COUNSELED ADULTS AND CHILDREN ON:

Possible side effects include deep vein thrombosis, pulmonary embolism, myocardial infarction and stroke

Not sharing POMALYST capsules with anyone—especially with females who can get pregnant
Not donating blood while taking POMALYST (including dose interruptions) and for 4 weeks after stopping POMALYST

Not breaking, chewing, or opening POMALYST capsules

Instructions on POMALYST dose and administration

Milligram (mg) Strength_________ Number of Capsules Dispensed_______

FEMALE CHILDREN (<18 YEARS OF AGE):

Parent or legal guardian must have read the POMALYST REMS™ education material and agreed to ensure compliance

Parent or legal guardian must inform the child’s doctor when the child begins menses
Checklist for male patients

☐ I will make sure that patients are aware that they will receive the Medication Guide along with their prescription

I COUNSELED ADULTS AND CHILDREN ON:

☐ Potential embryo-fetal toxicity and contraception (wearing a latex or synthetic condom every time when engaging in sexual intercourse with a female who can get pregnant)

☐ Female partners of males taking POMALYST® (pomalidomide) must call their healthcare provider right away if they get pregnant

☐ Possible side effects include deep vein thrombosis, pulmonary embolism, myocardial infarction and stroke

☐ Not sharing POMALYST capsules with anyone—especially with females who can get pregnant

☐ Not donating blood or sperm while taking POMALYST (including dose interruptions) and for 4 weeks after stopping POMALYST

☐ Not breaking, chewing, or opening POMALYST capsules

☐ Instructions on POMALYST dose and administration

Milligram (mg) Strength_______ Numbers of Capsules Dispensed__________

MALE CHILDREN (<18 YEARS OF AGE):

☐ Parent or legal guardian must have read the POMALYST REMS™ education material and agreed to ensure compliance
All boxes and spaces must be marked or filled in during counseling with the patient for every prescription.

Counselor Signature: ______________________  Date: ______________

For more information about POMALYST and the POMALYST REMS™ program, please visit www.CelgeneRiskManagement.com, or call the Celgene Customer Care Center at 1-888-423-5436.

Celgene Corporation
86 Morris Ave
Summit, NJ 07901

POMALYST is only available under a restricted distribution program, POMALYST REMSTM.

Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS, enclosed.

© 2015 Celgene Corporation  4/15  REMS-POM15645